Burkholderia cepacia is a group of closely related bacteria, formally called the Burkholderia cepacia complex (Bcc), found naturally in soil, water, and on plant roots. For most healthy people, these bacteria pose little threat. They become a serious concern in two specific settings: for people with cystic fibrosis or weakened immune systems, and as contaminants in water-based medical and consumer products.
Where Burkholderia Cepacia Lives
These bacteria are remarkably widespread in nature. They thrive in soil, freshwater, seawater, rivers, lakes, and around the root systems of plants. In one large survey across three U.S. cities, researchers tested soil and root zone samples from 91 sites, including playgrounds, parks, hiking trails, yards, and gardens. About 90% of those samples tested positive for Bcc organisms.
Bcc bacteria can also survive and multiply in environments with very few nutrients, which is what makes them such effective contaminants. They grow in drinking water, inside the biofilm that lines water pipes, and in any water-based liquid that provides even trace amounts of organic material. A study in Bologna, Italy found the bacteria in 3.5% of drinking water samples from public and private buildings, growing comfortably at around 24°C (75°F). Researchers at homes of cystic fibrosis patients have isolated multiple Bcc species from household soil and water, suggesting the home environment itself can act as a reservoir.
Why It Contaminates Medical Products
The ability to survive in low-nutrient liquids makes Bcc a persistent problem for pharmaceutical manufacturing. These bacteria have been found in an unusually wide range of products: intravenous drugs and solutions, nasal sprays, mouthwash, preoperative skin preparations, and hand sanitizers. Antiseptic solutions containing benzalkonium chloride are one of the most frequently contaminated product types.
Product recalls tied to Bcc contamination continue to occur. In 2025, DermaRite Industries expanded a voluntary nationwide recall covering hand sanitizers, skin cleansers, antifungal creams, skin protectants, wound care products, and foaming soaps, all due to potential Bcc contamination. The recalled products included items used in hospitals and long-term care facilities, such as perineal cleansers, diaper rash creams, and antiseptic soaps used after contact with patients. These types of recalls highlight how the bacteria can enter the supply chain through water used during manufacturing.
Who Is Most at Risk
Bcc infections overwhelmingly affect people whose lungs or immune systems are already compromised. Two groups face the greatest danger:
- People with cystic fibrosis (CF): Bcc bacteria have been recognized as particularly dangerous pathogens in CF since the late 1970s. The thick, sticky mucus in CF lungs creates an environment where these bacteria can adapt, establish themselves, and become virtually impossible to eliminate. Infection can cause rapid decline in lung function and significantly shorter survival.
- People with weakened immune systems: This includes hospitalized patients, those with chronic granulomatous disease (a rare immune deficiency), and people with conditions like diabetes. In one study of patients with Bcc bloodstream infections, the 28-day mortality rate was 41%.
For healthy individuals without underlying lung disease or immune problems, Bcc rarely causes serious illness.
How It Spreads
According to the CDC, Bcc spreads through several routes: exposure to contaminated water, soil, or watery environments; contact with contaminated surfaces or medical equipment; and person-to-person transmission. Direct spread between people occurs more commonly among cystic fibrosis patients, which is why many CF clinics enforce strict infection control measures, including separating patients who carry Bcc from those who don’t.
In hospital settings, contaminated equipment and water-based products are the primary vectors. Outbreaks have been traced to everything from IV fluids to moisturizing creams used on patient skin.
What Makes It Dangerous: Biofilms and Resistance
Two biological traits make Bcc infections so difficult to treat. The first is the bacteria’s ability to form biofilms, which are structured communities of bacteria encased in a self-produced protective matrix. This matrix shields the bacteria from the immune system, from environmental stress, and critically, from antibiotics. Biofilm formation is a hallmark of chronic Bcc infections in the lungs.
The second is extensive antibiotic resistance. Bcc bacteria are naturally resistant to many common antibiotics, not because they’ve acquired resistance from overuse, but because of built-in biological defenses. Their outer membrane has a unique structure that blocks certain drugs from binding, particularly polymyxins (a class of last-resort antibiotics used against many resistant bacteria). They also produce enzymes that break down other antibiotics before the drugs can work. In CF patients who receive repeated courses of antibiotics over their lifetime, resistance profiles tend to be even broader than in non-CF patients.
Cepacia Syndrome
The most feared outcome of Bcc infection in cystic fibrosis is cepacia syndrome, a rapidly progressing and often fatal pneumonia. It involves a sudden, sometimes unexpected deterioration in a patient’s condition, with severe inflammation and tissue destruction in the lungs. The progression from stable infection to cepacia syndrome can be unpredictable. Some CF patients carry Bcc for years without major problems, while others develop this life-threatening complication quickly.
How It’s Identified in the Lab
Identifying Bcc accurately is challenging because the bacteria closely resemble other species under standard testing. Routine methods like analyzing the fatty acid composition of bacterial cells cannot reliably distinguish between Bcc species. Laboratories use specialized selective growth media, such as Burkholderia Cepacia Selective Agar (BCSA), which contains antibiotics that suppress the growth of other bacteria while allowing Bcc to grow. A key feature of the medium’s design exploits the fact that Bcc bacteria cannot use lactose as a food source, helping separate them from look-alike organisms.
For definitive identification, labs analyze specific gene sequences. The 16S rRNA gene provides a general bacterial identification, while the recA gene is particularly useful for pinpointing which species within the Bcc complex is present. Automated systems that test which carbon sources the bacteria can and cannot metabolize provide additional confirmation. The U.S. Pharmacopeia first incorporated standardized testing methods for Bcc in pharmaceutical products in 2019, reflecting the growing recognition of contamination risk.
Treatment Challenges
The natural resistance of Bcc bacteria limits treatment options significantly. Most treatment relies on a specific class of antibiotics called extended-spectrum cephalosporins, because so many other drug classes are rendered ineffective by the bacteria’s built-in defenses. Even with appropriate antibiotics, outcomes can be poor. In the study of Bcc bloodstream infections, receiving the wrong initial antibiotic was an independent risk factor for death, underscoring how important rapid and accurate identification is. Treatment plans for CF patients with Bcc infections typically involve combinations of antibiotics, often delivered through multiple routes, tailored to the susceptibility profile of each individual patient’s strain.